Pluristyx and panCELLa Expand Intellectual Property Portfolio for Pluripotent Stem Cell Cloaking Technology
SEATTLE--(BUSINESS WIRE)--Today, Pluristyx, panCELLa, and Implant Therapeutics management are excited to announce their corporate merger, pending shareholder approval. The merged company will combine complementary portfolios to offer end-to-end customer support and provide increased access to a wide range of induced pluripotent stem cell (iPSC)-related products and services. The integrated technological and service offerings will greatly accelerate the development and delivery of revolutionary cell therapies to patients.
Merck, a leading science and technology company, announced that it has signed agreements licensing its CRISPR technology to two companies — PanCELLa, a cell therapy firm based in Toronto, Canada and Takara Bio, a biotechnology company based in Mountain View, California, USA.